Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis
Authors
Keywords
-
Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume 72, Issue 9, Pages 1475-1480
Publisher
BMJ
Online
2012-09-15
DOI
10.1136/annrheumdis-2012-201915
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Divergent requirement for Gαs and cAMP in the differentiation and inflammatory profile of distinct mouse Th subsets
- (2012) Xiangli Li et al. JOURNAL OF CLINICAL INVESTIGATION
- Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
- (2012) Kim Papp et al. LANCET
- 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
- (2011) J. Braun et al. ANNALS OF THE RHEUMATIC DISEASES
- Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression
- (2010) G. R. Heiland et al. ANNALS OF THE RHEUMATIC DISEASES
- Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register
- (2010) E. Lie et al. ANNALS OF THE RHEUMATIC DISEASES
- Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis
- (2010) Fiona E McCann et al. ARTHRITIS RESEARCH & THERAPY
- Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints
- (2009) S. Uderhardt et al. ANNALS OF THE RHEUMATIC DISEASES
- Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis
- (2009) Heiner Appel et al. ARTHRITIS AND RHEUMATISM
- Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis
- (2009) Dimitrios Daoussis et al. ARTHRITIS AND RHEUMATISM
- Phosphodiesterase 3 and 4 Negatively Regulate Receptor Activator of Nuclear Factor-κB Ligand-Mediated Osteoclast Formation by Prostaglandin E2
- (2009) A Long Sae Mi Noh et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis
- (2009) PH Schafer et al. BRITISH JOURNAL OF PHARMACOLOGY
- Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling
- (2009) Katia Boniface et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
- (2009) Steven R. Cummings et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years
- (2009) Désirée van der Heijde et al. ARTHRITIS RESEARCH & THERAPY
- Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis
- (2008) Désirée van der Heijde et al. ARTHRITIS AND RHEUMATISM
- Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept
- (2008) D. van der Heijde et al. ARTHRITIS AND RHEUMATISM
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now